Cobicistat - TYBOST oral tablets | GlobalRPh Renal Dosing Master

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Review first - source-specific qualification

A creatinine-secretion effect must not mask genuine renal injury

The mirror separates inhibition of creatinine secretion from TDF-associated renal injury and combination-specific restrictions.

Before applying: Assess the full regimen and renal-safety findings; do not dismiss every creatinine rise or transfer TDF rules to TAF.

Evidence for this qualification

Selected-source qualification; independent clinician review pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (1)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Rxlist source

GlobalRPh RX List - TYBOST

Product / population: TYBOST cobicistat as a pharmacokinetic enhancer; renal restrictions depend on the complete antiretroviral regimen, including TDF versus TAF.
Renal measure: Estimated CrCl in mL/min; creatinine secretion affects interpretation

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Before using this finding

Distinguish a secretion effect from concurrent kidney injury.

Check the entire combination; this is not an automated interaction clearance.

Selected named sections only; not a complete monograph or independent clinical approval.

A label mirror is not independent corroboration of its underlying label. Fresh official confirmation is pending unless a separate official card is shown.

Renal dosing, restrictions and evidence limits

Cobicistat can lower creatinine-based estimates by inhibiting tubular creatinine secretion without reducing measured glomerular function. The mirror nevertheless calls for close renal-safety monitoring when a confirmed serum-creatinine increase exceeds 0.4 mg/dL from baseline.

TYBOST with tenofovir disoproxil fumarate is not recommended below estimated CrCl 70 mL/min in this source. Renal injury, including Fanconi syndrome, has been reported with TDF-containing regimens. With TDF, assess urine glucose/protein and estimated clearance at baseline and during treatment; assess phosphorus when renal impairment or risk is present.

Do not presume every creatinine rise is benign or transfer this TDF-specific rule to TAF combinations.

Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-10. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/tybost-drug/

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation

Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

GlobalRPh RX List - TYBOST

Authored v5.9; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

No dialysis regimen established in selected content

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

GlobalRPh RX List

GlobalRPh RX List - TYBOST

Interaction-dependent renal restriction. Review the complete coadministered regimen; a single-product renal statement does not clear combination risk.

Before using this finding

Distinguish a secretion effect from concurrent kidney injury.

Check the entire combination; this is not an automated interaction clearance.

Dialysis evidence: No dialysis regimen established in selected content

TYBOST cobicistat as a pharmacokinetic enhancer; renal restrictions depend on the complete antiretroviral regimen, including TDF versus TAF.

Renal method: Estimated CrCl in mL/min; creatinine secretion affects interpretation
Retrieved: 2026-09-10

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

A creatinine-secretion effect must not mask genuine renal injury

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds

Find text within this drug

Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance

Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Jump to renal guidance Read 1 difference / caution notes Clinician guide

Only one eligible source version is stored here. No second source is inferred from a reference link. Independent corroboration is still needed.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Source-review outline (read-only; copy and complete elsewhere)

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Population Kidney-function trend Renal replacement setting

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

renal measure and combination restriction

A creatinine-secretion effect must not mask genuine renal injury

The mirror separates inhibition of creatinine secretion from TDF-associated renal injury and combination-specific restrictions.

How to use this: Assess the full regimen and renal-safety findings; do not dismiss every creatinine rise or transfer TDF rules to TAF.

GlobalRPh RX List - TYBOST Darunavir/cobicistat/emtricitabine/TAF (SYMTUZA)Elvitegravir/cobicistat/emtricitabine/TAF (GENVOYA)

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

Rxlist source

GlobalRPh RX List - TYBOST

TYBOST cobicistat as a pharmacokinetic enhancer; renal restrictions depend on the complete antiretroviral regimen, including TDF versus TAF.

Method: Estimated CrCl in mL/min; creatinine secretion affects interpretation

Renal dosing, restrictions and evidence limits Read this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scope GlobalRPh RX List - TYBOST

Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/tybost-drug/

Exact product and population

TYBOST cobicistat as a pharmacokinetic enhancer; renal restrictions depend on the complete antiretroviral regimen, including TDF versus TAF.

RDM59-SCOPE-cobicistat-tybost · Source section: Selected source product scopeRenal section finder

Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist Compare this source

GlobalRPh RX List - TYBOST

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · TYBOST cobicistat as a pharmacokinetic enhancer; renal restrictions depend on the complete antiretroviral regimen, including TDF versus TAF.

Renal method: Estimated CrCl in mL/min; creatinine secretion affects interpretation
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-10

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.

Interaction-dependent renal restriction. Review the complete coadministered regimen; a single-product renal statement does not clear combination risk.

Before using this finding

Distinguish a secretion effect from concurrent kidney injury.

Check the entire combination; this is not an automated interaction clearance.

Dialysis evidence: No dialysis regimen established in selected content

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Do not presume every creatinine rise is benign or transfer this TDF-specific rule to TAF combinations.

RDM59-rxlist-cobicistat-tybost-81ccdbbd03-C1 · Source locator: Precautions: Effects on Serum Creatinine; New or Worsening Renal Impairment with TDF

Source-specific limits

Selected named sections only; not a complete monograph or independent clinical approval.

A label mirror is not independent corroboration of its underlying label. Fresh official confirmation is pending unless a separate official card is shown.

Source identity and provenance

Source family: product_label_mirror
Source: https://globalrph.com/rx-list/tybost-drug/
Retrieved: 2026-09-10
Renal-function method: Estimated CrCl in mL/min; creatinine secretion affects interpretation
Source date/version: Source revision date not established in selected retrieval.
Hash meaning: SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256: bdec5e63b082c0e46e3fc06bf6779a6a9784cabbe97570f8d9591235cb49a041

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source: https://globalrph.com/rx-list/tybost-drug/
Source retrieval: 2026-09-10. This is not the source publication or label revision date.
Original source type: rxlist summary
Local text SHA-256: 349b0a68ab8b29dbf2d837662d1225e9e47e061bd034bd07c5cf811970f08ea7
Import versus clinical validation: Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report